




Vaccine

journal homepage: www.elsevier.com/locate/vaccine



Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older

Lisa A. Jackson^{a,*}, Alejandra Gurtman^b, Martin van Cleeff^c, Robert W. Frencck^d, John Treanor^e, Kathrin U. Jansen^b, Daniel A. Scott^b, Emilio A. Emini^b, William C. Gruber^b, Beate Schmoele-Thoma^f

^a The Group Health Research Institute, Group Health, Seattle, Washington, United States

^b Pfizer Inc, Pearl River, New York, United States

^c Triangle Medical Research Associates, Cary, North Carolina, United States

^d Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

^e University of Rochester Medical Center, Rochester, New York, United States

^f Pfizer GmbH, Berlin, Germany

ARTICLE INFO

Article history:

Received 4 January 2013

Received in revised form 11 April 2013

Accepted 26 April 2013

Available online 18 May 2013

Keywords:

Adult

Pneumococcal conjugate vaccine

Recall responses

ABSTRACT

Background: Unlike free polysaccharide vaccines, pneumococcal polysaccharide conjugate vaccines (PCVs) induce a T cell-dependent immune response and have the potential to provide an extended duration of protection with repeated vaccinations.

Methods: This was an extension of a previous study in pneumococcal vaccine-naïve adults aged 50–64 years in which adults 60–64 years of age were given 13-valent PCV (PCV13) or 23-valent pneumococcal polysaccharide vaccine (PPSV23) and adults aged 50–59 were given PCV13. In this follow up study conducted about 4 years later, the 60–64 year olds initially given PCV13 received PCV13 or PPSV23, and those initially given PPSV23 received another PPSV23. All adults aged 50–59 years were re-vaccinated with PCV13. Anti-pneumococcal opsonophagocytic activity (OPA) titers were measured before and 1 month after vaccination.

Results: A second PCV13 given about 4 years after a first vaccination induced OPA titers that were significantly higher than those following the initial vaccination for 7 of 13 serotypes in the older group, and 6 of 13 serotypes in the younger group, and responses to the remaining serotypes were largely non-inferior. In contrast, OPA titers following revaccination with PPSV23 were statistically significantly lower for 9 of the 13 serotypes, and non-inferior for the remaining serotypes, when compared to the responses to the first PPSV23. OPA titers in the older adults who received PPSV23 after initial PCV13 were significantly higher than those following a first PPSV23 for 10 of the 13 serotypes.

Conclusion: In adults 50 to 64 years of age, initial vaccination with PCV13 establishes an immune state that results in recall anti-pneumococcal responses upon subsequent vaccination with either conjugated or free polysaccharide vaccine. In contrast, initial vaccination with PPSV23 results in an immune state in which subsequent PPSV23 administration yields generally lower responses compared with the initial responses.

© 2013 The Authors. Published by Elsevier Ltd. Open access under [CC BY-NC-ND license](http://creativecommons.org/licenses/by-nc-nd/4.0/).

Abbreviations: ACIP, United States Advisory Committee on Immunization Practices; AE, adverse event; CI, confidence interval; CRM₁₉₇, cross-reactive material 197; GMR, geometric mean ratio; GMT, geometric mean titer; OPA, opsonophagocytic activity; PCV, pneumococcal polysaccharide conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent polysaccharide vaccine; RCDC, reverse cumulative distribution curve; SAE, serious adverse event.

* Corresponding author at: Group Health Research Institute, 1730 Minor Ave, Ste 1600, Seattle, WA 98101, United States. Tel.: +1 206 442 5216.

E-mail addresses: jackson.l@ghc.org (L.A. Jackson), alejandra.gurtman@pfizer.com (A. Gurtman), mvanclieff@carymedicalgroup.com (M. van Cleeff), robert.frenck@cchmc.org (R.W. Frencck), john.treanor@urmc.rochester.edu (J. Treanor), kathrin.jansen@pfizer.com (K.U. Jansen), dan.scott@pfizer.com (D.A. Scott), emilio.emini@pfizer.com (E.A. Emini), bill.gruber@pfizer.com (W.C. Gruber), beate.schmoele-thoma@pfizer.com (B. Schmoele-Thoma).




Fig. 1. Study design and disposition of subjects.

Vaccinations received as part of the initial study are shown in the striped boxes [5]. Abbreviations: PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.

1. Introduction

The incidence and mortality of pneumococcal disease in adults increase with advancing age [1,2]. A 23-valent pneumococcal vaccine containing free (unconjugated) polysaccharides (PPSV23) has been available for 30 years and a single vaccination is recommended for adults ≥ 65 years and for younger adults with certain chronic medical conditions or other indications [2]. Revaccination is not routinely indicated in part due to the diminished immune responses that have been observed following revaccination, which may be due to the T cell independent nature of the immune response [2,3]. In contrast to PPSV23, the 13-valent pneumococcal conjugate vaccine (PCV13) was designed to engender T cell-dependent immunity, inducing a recall response on subsequent bacterial exposure or revaccination with the potential to significantly prolong the protection afforded by the vaccine.[4]

A previous clinical study of pneumococcal vaccine-naïve adults 50 through 64 years of age evaluated the functional opsonophagocytic activity (OPA) anti-pneumococcal immune responses elicited by a first vaccination with PCV13 or PPSV23. PCV13 was immunogenic and, in adults 60–64 years of age that were randomized to receive PCV13 or PPSV23, PCV13 elicited significantly higher OPA titers than those elicited by PPSV23 for 9 of 12 serotypes common to both vaccines. Adults 50–59 years of age all received PCV13, and had generally higher OPA titers than observed in adults 60–64 years of age who received PCV13 [5].

This follow-up study was conducted 3.5–4 years after the previous study in order to evaluate the immune responses to a second PCV13 and to a second PPSV23, and to determine the influence of initial PCV13 immunization on the responses to a subsequent PPSV23 vaccination in the adults 60–64 years of age who received PCV13.

2. Methods

2.1. Study design and populations

This was an extension of a previous study in pneumococcal vaccine-naïve adults 50 through 64 years of age, conducted at 23 medical centers in the United States [5]. Both studies were undertaken in accordance with the Declaration of Helsinki and Good Clinical Practice [6,7]. In the initial study, adults 60–64 years of age were randomly assigned with equal probability to receive PCV13 or PPSV23 and those 50–59 years of age received open label PCV13. In this extension study conducted 3.5–4 years after the start of the previous study, informed consent was obtained as for a new study and adults in the 60–64 year old age group who had initially received PCV13 were randomized 1:1 to receive PCV13 or PPSV23, and those who had received PPSV23 received another PPSV23 vaccination. Adults in the 50–59 year old age group received a second PCV13 (Fig. 1).

Table 1
Baseline characteristics.

Characteristic	60–64 Year age group			50–59 Year age group
	PCV13/PCV13 N = 108	PCV13/PPSV23 N = 108	PPSV23/PPSV23 N = 189	PCV13/PCV13 N = 214
Female, %	57.4	50.0	64.0	63.1
Race, %				
White	98.1	96.3	94.7	94.9
Black	0.0	0.9	1.6	3.7
Asian	0.0	0.9	0.5	1.4
Other	0.9	0.0	2.1	0.0
Indian or Alaska Native	0.9	1.9	0.5	0.0
Native Hawaiian or Other Pacific Islander	0.0	0.0	0.5	0.0
Hispanic or Latino, %	0.9	2.8	3.2	0.0
Mean age at vaccination 1, years (SD)	61.6 (1.4)	61.7 (1.3)	61.6 (1.4)	54.4 (2.9)
Time since vaccination 1, years (SD)	3.7 (0.1)	3.7 (0.1)	3.7 (0.1)	3.5 (0.1)
Mean age at vaccination 2, years (SD)	65.3 (1.4)	65.3 (1.4)	65.3 (1.4)	57.9 (2.9)

The study populations for both studies included persons with stable pre-existing underlying chronic conditions (e.g., cardiovascular, pulmonary, renal, liver diseases including alcoholic liver disease and alcoholism, and diabetes mellitus). Disease had to be stable, defined as not requiring significant change in therapy or hospitalization for worsening disease 12 weeks prior to vaccination. Participants were excluded if they had serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, impaired immune function, or had previously received a PPSV23 dose or any prior PCV.

Non-study medications were permitted. Licensed vaccines, except pneumococcal vaccines, could be given according to local or national recommendations, and could be administered concomitantly. Receipt of influenza vaccine was permitted, if it was given at least 14 days before or after study vaccination.

Clinic visits occurred at vaccination and 1 month (29–43 days) after vaccination with a telephone visit for a safety assessment at 6 months after vaccination. Blood samples were obtained before and 1 month after vaccination.

2.2. Vaccines and administration

PCV13 (Prevnar 13/Prevenar 13[®], Wyeth Vaccines; Lot Number 7-5095-010A) contains polysaccharides of pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, and 23F individually conjugated to a nontoxic mutant form of diphtheria toxin cross-reactive material 197 (CRM₁₉₇). Each 0.5 mL dose contains 2.2 µg of each serotype, except type 6B, which is included at 4.4 µg. Each dose is formulated in 5.0 mM succinate and 0.85% sodium chloride at pH 5.8 with 0.125 mg aluminum as aluminum phosphate and 0.02% polysorbate 80. The vaccine is supplied in single-dose syringes without preservatives and stored at 2–8 °C.

PPSV23 (Pneumovax 23[®], Merck & Company, Inc; Lot Number A08071-003L) consists of a purified capsular polysaccharide from 12 of the serotypes included in PCV13 (all except 6A), as well as 11 additional serotypes (2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F). The vaccine is formulated to contain 25 µg of each of the 23 purified polysaccharide serotypes per 0.5 mL dose of vaccine, contains phenol as a preservative and stored at 2–8 °C.

Vaccines were administered by intramuscular injection in the deltoid using 25 G 1 in. needles.

2.3. Study objectives

In the older age group, the primary study objective was to evaluate the response to PPSV23 after an initial dose of PCV13 or PPSV23 for the 12 serotypes common to both vaccines and for serotype 6A

which is unique to PCV13. Secondary objectives were to evaluate the ability of PCV13 to maintain or enhance OPA responses when given 3.5–4 years after an initial dose of PCV13 in both age groups, and describe the immune responses following 2 consecutive doses of PPSV23 in the older age group for the 12 serotypes common to both vaccines and for serotype 6A. Additionally, various immune response comparisons were performed as described in the Results section.

2.4. Analysis populations

The evaluable immunogenicity population was the primary population for immunogenicity analyses and consisted of eligible subjects who had at least one valid and determinate assay result in this extension study, received both study vaccines as assigned and no prohibited vaccines, and had no other major protocol violation.

2.5. Immunogenicity assessments

Primary endpoints were the functional antibacterial OPA titers for the 13 serotypes in PCV13 measured using serotype-specific validated OPA assays in samples obtained immediately before and approximately 1 month after each vaccination [8].

2.6. Safety assessments

Participants recorded local reactions (redness, swelling, pain and limitation of arm movement of the injected arm), and systemic events (chills, fatigue, headache, vomiting, decreased appetite, rash, new generalized muscle pain, aggravated generalized muscle pain, new generalized joint pain, and aggravated generalized joint pain), and oral temperature in an electronic diary on the evening of vaccination and for the next 13 days. Adverse events (AEs) were collected from enrollment through the month 1 postvaccination visit, serious adverse events (SAEs) from enrollment through the month 6 follow-up phone contact, and deaths through the end of the study.

2.7. Statistical analysis

2.7.1. Sample size considerations

All subjects who received the first vaccination and satisfied eligibility criteria to receive a second vaccination were included in the analyses. No formal power calculation was done.

2.7.2. Immunogenicity analyses

All analyses were descriptive and were done using the SAS software package. The non-inferiority criterion used in the previous study was applied in this study. No imputations were done for

missing data. For the comparison of post-vaccination OPA GMTs between vaccine groups or sequences, the 2-sided 95% confidence interval (CI) on the geometric mean ratio (GMR) for each serotype was calculated (back-transformed 95% CI for mean difference on the logarithmic scale computed using the Student *t* distribution). For comparisons within a vaccine sequence, analyses were performed using data only from those subjects who had OPA assessments after both vaccinations. Noninferiority was declared if the lower limit of the 2-sided 95% CI for the GMR was greater than 0.5 (2-fold criterion). This value was selected based on matching immunogenicity to efficacy results from several infant 7-valent Pneumococcal polysaccharide conjugate vaccine (PCV) or 9-valent PCV efficacy trials [9]. A secondary analysis assessed statistically significantly greater or lower responses; a statistically greater response was declared if the lower limit of the 95% CI for the GMR was >1.0, and a statistically lower response was declared if the upper limit of the 95% CI for the GMR was <1.0.

Reverse cumulative distribution curves (RCDC) for key comparisons were generated to permit comparisons of immune response throughout the full range of OPA responses

2.7.3. Safety analyses

Comparisons of the incidence of local reactions and systemic events between vaccine groups were performed with corresponding 95% CIs and *p*-values based on Chan and Zhang methodology [10].

3. Results

3.1. Baseline characteristics and disposition of subjects

A total of 405 subjects 60–64 years of age at enrollment in the initial study participated in the extension study. Of those, 216 had received PCV13 in the initial study and were randomized to receive PCV13 (*N* = 108) or PPSV23 (*N* = 108) in the extension study, and 189 had received PPSV23 in the initial study and received PPSV23 in the extension study, with all being evaluable. Additionally, 214 of subjects 50–59 years of age at initial study enrollment participated in the extension study and received a second PCV13 vaccination, with 211 being evaluable. In total, 50.1% of subjects who received vaccination 1 in the initial study returned for this extension study (Table 1, Fig. 1).

The mean ages of subjects in the 60–64 year age group and in the 50–59 year age group were 65.3 years and 57.9 years, respectively, at vaccination 2. The mean intervals since initial vaccination were 3.7 (range 3.6–3.9) and 3.5 (range 3.3–3.6) years, respectively.

The race and ethnicity of subjects was similar across the total study population with the majority of subjects being white (94.7–98.1%). In adults aged 60–64 years, more females were vaccinated in the PCV13/PCV13 and PPSV23/PPSV23 groups (57.4% and 64.0% respectively) compared to the PCV13/PPSV23 group (50.0%), and in the younger cohort, who all received PCV13/PCV13, 63.1% of subjects were female (Table 1).

In the older and younger age groups 25.9% and 19.2%, respectively, reported chronic underlying diseases.

3.2. Immune responses

3.2.1. PPSV23 following initial PCV13 (PCV13/PPSV23) compared to initial PPSV23

OPA geometric mean titers (GMTs) following PPSV23 administered after PCV13 were statistically significantly greater for 10 of 13 serotypes (1, 3, 5, 6A, 6B, 7F, 18C, 19A, 19F, 23F) and non-inferior for the remainder (4, 9V, 14), when compared to responses following initial PPSV23 administered in the previous study (Table 2).

Table 2 Comparison of pneumococcal OPA GMTs following revaccination in the 60–64 year age group initially vaccinated with PCV13.

Serotype	PCV13/PPSV23 vs. PPSV23		PCV13/PPSV23 vs. PCV13		PCV13/PCV13 vs. PCV13		Ratio	GMT ratio ^{c,d} (95% CI)
	PCV13/PPSV23 <i>n</i> ^a = 99–107 GMT ^b	PPSV23 <i>n</i> ^a = 167–184 GMT ^b	PCV13/PPSV23 <i>n</i> ^a = 88–100 GMT ^b	PCV13 <i>n</i> ^a = 88–100 GMT ^b	PCV13/PCV13 <i>n</i> ^a = 92–102 GMT ^b	PCV13 <i>n</i> ^a = 92–102 GMT ^b		
1	398	116	377	172	334	155	2.2 (1.64–2.94)	2.2 (1.59–2.92)
3	164	105	162	102	87	102	1.6 (1.23–2.03)	0.9 (0.68–1.08)
4	1875	1420	1997	2894	1194	1626	0.7 (0.51–0.94)	0.7 (0.53–1.01)
5	476	149	445	239	277	180	1.9 (1.37–2.53)	1.5 (1.09–2.16)
6A ^e	832	274	812	2884	2126	2411	0.3 (0.21–0.37)	0.9 (0.64–1.21)
6B	2670	1088	2707	2664	4357	2312	1.0 (0.79–1.31)	1.9 (1.42–2.50)
7F	1895	403	1818	971	1226	928	1.9 (1.25–2.80)	1.3 (0.89–1.95)
9V	1089	654	909	1474	855	1163	0.6 (0.42–0.91)	0.7 (0.46–1.17)
14	1268	824	1367	655	1040	746	2.1 (1.43–3.04)	1.4 (1.01–1.93)
18C	2489	1135	2503	2136	1837	1529	1.2 (0.92–1.49)	1.2 (0.93–1.55)
19A	966	377	976	765	791	591	1.3 (1.05–1.55)	1.3 (1.06–1.68)
19F	1653	621	1670	675	989	467	2.5 (1.69–3.61)	2.1 (1.48–3.04)
23F	299	86	333	432	918	448	0.8 (0.56–1.07)	2.1 (1.40–3.01)

^a *n* = Number of subjects with determinate OPA titer for the specified serotype.

^b GMTs calculated using all evaluable subjects with data for a given blood draw.

^c Ratio of GMTs calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.

^d For within group comparisons the GMT ratio (95% CI) accounts for each subject as their own control across time and GMTs are derived for subjects with data at both time points.

^e Serotype 6A is not included in PPSV23.

Table 3
Pneumococcal OPA GMTs following revaccination with PCV13 in 50–59 year old subjects initially vaccinated with PCV13 and comparison of pneumococcal OPA GMTs following vaccination with 13vPnC/13vPnC in 60–64 year old subjects and 50–59 year old subjects.

Serotype	PCV13/PCV13 vs PCV13 (Adults 50–59 years of age)			PCV13/PCV13 (Adults 50–59 years of age vs. Adults 60–64 years of age)		
	PCV13/PCV13 <i>n</i> ^a = 181–202 GMT ^b	PCV13 <i>n</i> ^a = 181–202 GMT ^b	Ratio GMT ratio ^{c,d} (95% CI)	50–59 years of age <i>n</i> ^a = 196–205 GMT ^b	60–64 years of age <i>n</i> ^a = 100–104 GMT ^b	Ratio GMT ratio ^c (95% CI)
1	296	198	1.5 (1.20–1.86)	292	334	0.9 (0.63–1.22)
3	85	91	0.9 (0.80–1.08)	83	87	1.0 (0.73–1.26)
4	1685	2817	0.6 (0.49–0.73)	1657	1175	1.4 (1.07–1.86)
5	291	235	1.2 (1.02–1.50)	293	276	1.1 (0.71–1.58)
6A ^e	3143	4347	0.7 (0.6–0.87)	3104	2064	1.5 (1.05–2.16)
6B	4886	3085	1.6 (1.29–1.95)	4885	4184	1.2 (0.88–1.54)
7F	1659	1596	1.0 (0.83–1.30)	1654	1223	1.4 (1.06–1.73)
9V	1492	1933	0.8 (0.61–0.98)	1421	770	1.8 (1.23–2.77)
14	1278	865	1.5 (1.15–1.90)	1186	1031	1.1 (0.85–1.55)
18C	2156	1742	1.2 (0.96–1.59)	2066	1918	1.1 (0.79–1.46)
19A	1048	959	1.1 (0.94–1.27)	1039	789	1.3 (1.01–1.72)
19F	1182	633	1.9 (1.51–2.32)	1171	958	1.2 (0.88–1.70)
23F	1188	563	2.1 (1.63–2.73)	1158	867	1.3 (0.90–1.99)

^a *n* = Number of subjects with determinate OPA titer for the specified serotype.

^b GMTs calculated using all evaluable subjects with data for a given blood draw.

^c Ratio of GMTs calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.

^d For within group comparisons the GMT ratio (95% CI) accounts for each subject as their own control across time and GMTs are derived for subjects with data at both time points.

^e Serotype 6A is not included in PPSV23.

3.2.2. PCV13/PPSV23 compared to initial PCV13

OPA GMTs following PPSV23 administered after PCV13 were statistically significantly greater for 7 of 13 serotypes (1, 3, 5, 7F, 14, 19A, 19F) and met non-inferiority criteria for 4 of the remaining 6 serotypes (4, 6B, 18C, 23F) when compared to responses following initial PCV13 administered in the previous study (Table 2). The OPA GMTs were significantly lower for 3 serotypes (4, 6A, 9V); nonetheless, the 95% CI upper bounds for 2 of these serotypes (4 and 9V) were ≥ 0.91 suggesting generally comparable responses when comparing the first and second vaccine administrations. Only the serotype 6A response following PPSV23 administration was clearly lower than after initial PCV13, reflecting the absence of this serotype in PPSV23 (Table 2).

3.2.3. PCV13/PCV13 compared to initial PCV13

OPA GMTs following 2 administrations of PCV13 were statistically significantly greater compared to a single administration of PCV13 for 7 of 13 serotypes (1, 5, 6B, 14, 19A, 19F, 23F) in adults 60–64 years of age (Table 2), and 6 of 13 serotypes (1, 5, 6B, 14, 19F, 23F) in adults 50–59 years of age (Table 3). Responses to the remaining serotypes were largely non-inferior, although 3 serotypes (4, 6A, 9V) yielded statistically inferior responses in the younger age group.

3.2.4. PPSV23/PPSV23 compared to initial PPSV23

OPA GMTs following 2 doses of PPSV23 were statistically significantly lower for 9 of the 13 serotypes (3, 4, 5, 6A, 9V, 14, 18C, 19F, 23F), and non-inferior for the remaining 4 serotypes (1, 6B, 7F, 19A) (Table 4).

3.2.5. PCV13/PPSV23 compared to PPSV23/PPSV23

OPA GMTs following administration of PPSV23 to persons who had previously received PCV13 were statistically significantly greater for all serotypes compared to the responses to PPSV23 given to persons who had previously received PPSV23 (Table 4).

3.2.6. PCV13/PCV13 compared to PPSV23/PPSV23

OPA GMTs following a second dose of PCV13 were statistically significantly greater for all common serotypes compared to responses following a second dose of PPSV23 (Table 4).

3.2.7. PCV13/PCV13 in younger adults compared to PCV13/PCV13 in older adults

OPA GMTs after 2 doses of PCV13 in the younger age group were statistically significantly greater for 5 serotypes (4, 6A, 7F, 9V, 19A) (Table 3).

3.3. Population responses

RCDCs showing the population anti-pneumococcal OPA responses in adults 60–64 years of age for the vaccination sequences PCV13/PCV13, PCV13/PPSV23, and PPSV23/PPSV23 confirm the results obtained when comparing OPA GMTs (Supplemental Figs. S1, S2, S3). Depending on serotype, responses throughout the vaccinated population were higher or comparable following administration of PPSV23 or PCV13 given after an initial administration of PCV13. In contrast, population responses were consistently lower following 2 consecutive doses of PPSV23.

3.4. Safety

Local reactions were generally mild across all groups. Incidences of local reactions in subjects receiving 2 sequential doses of PCV13, or PCV13 followed by PPSV23, were generally lower than for subjects receiving 2 doses of PPSV23 (Table 5). An increase in local reactions was seen after a second dose of PPSV23 compared to a first (Table 5). Muscle pain, fatigue, and headache were the most common systemic events after each vaccination (Table 5). Fever was rare and no severe fever was reported. Most adverse events (AEs) were conditions commonly observed among older adults, and no vaccine related serious adverse events (SAEs) or deaths were reported.

4. Discussion

Although the incidence and mortality of pneumococcal disease increase with age among older adults, the current recommended use of PPSV23 does not allow for maintenance of the vaccine-elicited protective immune response over the period of risk. This vaccine is not generally recommended for adults 50–64 years of age and, in the United States, only a single administration is

Table 4
Comparison of pneumococcal OPA immune responses following revaccination in the 60–64 year age group initially vaccinated with PPSV23.

Serotype	PPSV23/PPSV23 vs PPSV23 (Adults 60–64 years of age)		PCV13/PPSV23 vs PPSV23 (Adults 60–64 years of age)		PCV13/PCV13 vs PPSV23/PPSV23 (Adults 60–64 years of age)	
	PPSV23 n ^a = 157–181 GMT ^b	Ratio GMT ratio ^{c,d} (95% CI)	PCV13/PPSV23 n ^a = 99–107 GMT ^b	PPSV23/PPSV23 n ^a = 174–186 GMT ^b	PCV13/PCV13 n ^a = 100–104 GMT ^b	PPSV23/PPSV23 n ^a = 174–186 GMT ^b
1	95	0.8 (0.68–1.02)	398	95	334	95
3	53	0.5 (0.44–0.59)	164	53	87	53
4	725	0.5 (0.40–0.64)	1875	733	1175	733
5	71	0.5 (0.39–0.56)	476	74	276	74
6A ^e	133	0.5 (0.35–0.62)	832	123	2064	123
6B	915	0.8 (0.62–1.04)	2670	916	4184	916
7F	466	1.1 (0.81–1.37)	1895	497	1223	497
9V	181	0.3 (0.18–0.41)	1089	187	770	187
14	619	0.8 (0.60–0.95)	1268	661	1031	661
18C	822	0.8 (0.60–0.94)	2489	802	1918	802
19A	361	1.0 (0.83–1.12)	966	364	789	364
19F	405	0.7 (0.57–0.81)	1653	374	958	374
23F	56	0.6 (0.50–0.76)	299	54	867	54
						Ratio GMT ratio ^c (95% CI)
						3.5 (2.39–5.14)
						1.6 (1.19–2.28)
						1.6 (1.05–2.44)
						3.7 (2.32–6.04)
						16.8 (9.45–29.87)
						4.6 (2.92–7.15)
						2.5 (1.56–3.89)
						4.1 (2.22–7.65)
						1.6 (1.07–2.26)
						2.4 (1.54–3.72)
						2.2 (1.52–3.08)
						2.6 (1.68–3.92)
						15.9 (9.33–27.19)

^a n = Number of subjects with determinate antibody titer to the specified serotype.

^b GMTs calculated using all available subjects with available data for a given blood draw.

^c Ratio of GMTs calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.

^d For within group comparisons the GMT ratio (95% CI) accounts for each subject as their own control across time and GMTs are derived for subjects with data at both time points.

^e Serotype 6A is not included in PPSV23.

recommended for adults ≥ 65 years [2,3,11]. Although not invariably observed, re-immunization with PPSV23 has been repeatedly shown to elicit lower antibody responses following revaccination, compared to the responses after initial administration [11,12]. Of interest, similar observations have been made with other free polysaccharide vaccines, such as *Neisseria meningitidis* capsular polysaccharide vaccines [4,14,15]. The underlying mechanism for the blunting of the immune response with revaccination is not fully understood, but may be due to the loss of memory B cells upon initial or follow-on administration of free polysaccharides [16–18].

By contrast, an efficient recall response is seen with PCVs like PCV13 in which the polysaccharide is covalently attached to an immunological “carrier” protein converting the T cell-independent immune response elicited by PPSV23 to a T cell-dependent immune response [17–20]. Therefore, PCV13 may induce a qualitatively different immune response than that elicited by PPSV23, resulting in immunological memory and an improved immune response upon subsequent vaccine administration of PCV13 or PPSV23 with the potential for re-immunization to provide protection for a lifetime of risk. ACIP recently recommended that certain immunocompromised populations be vaccinated with PCV13 first followed by a dose of PPSV23 [21].

In this study, subjects in both age groups who received PCV13 in the previous study generally had robust responses to either PCV13 or PPSV23 given in the current study. Among persons who received a second dose of PCV13, responses to the second vaccination were generally at least comparable to initial PCV13 responses and statistically significantly greater for many of the serotypes. Among persons who received PCV13 in the original study and PPSV23 in this extension study, the responses following the PPSV23 were significantly greater for most of the serotypes common to both vaccines than those observed in persons who received an initial dose of PPSV23 in the original study.

The recall immune responses seen after re-vaccination with PCV13 in the current study are in contrast to previously reported results. In previous studies, neither administration of a second dose of PCV13 one year after an initial dose of PCV13 nor a dose of PPSV23 administered 3–6 months after a dose of PCV7 demonstrated an apparent immunological recall [22–25]. It is possible that a longer interval between PCV13 administration and a second dose of PCV13 or a dose of PPSV23 is required to optimize immune responses to subsequent doses of pneumococcal vaccine after an initial dose of conjugated vaccine. These results support the perspective that the conjugate vaccine is capable of eliciting polysaccharide-specific immunological memory.

In contrast, administration of a second dose of PPSV23 to persons who had received PPSV23 in the original study led to notably lower immune responses than those observed following the initial PPSV23. The lack of immunological memory elicited by PPSV23 stands in contrast to the apparent memory elicited by PCV13, and reflects previously reported observations with similar vaccines [26]. The immunological advantage of the PCV compared to the free (unconjugated) polysaccharide vaccine is most notable when comparing the OPA responses after 2 doses of PCV13 with those following 2 doses of PPSV23. An OPA threshold for protection has not been identified, but the population responses as reflected by the RDCs demonstrate the immunologic advantage of the PCV13 throughout the full distribution of OPA responses for a number of serotypes. Hence, whatever the threshold, PCV13 alone or as a successive dose is likely to improve protection, compared to single or successive doses of PPSV23 for serotypes common to both vaccines.

Finally, responses after 2 PCV13 doses in 50–59 year olds were noninferior to the responses in the older age group and statistically significantly greater for 5 serotypes, demonstrating a not unexpected greater immune response in younger compared to older adults.

Table 5
Local reactions and systemic events reported up to day 14 after vaccination 1 and vaccination 2.

		Adults 60–64 years of age						Adults 50–59 years of age					
		PPSV23/PPSV23 vs. PPSV23			PCV13/PPSV23 vs. PCV13			PCV13/PCV13 vs. PCV13			PCV13/PCV13 vs. PCV13		
		PPSV23/PPSV23%	PPSV23%	Difference ^d (95% CI)	PCV13/PPSV23%	PCV13%	Difference ^d (95% CI)	PCV13/PCV13%	PCV13%	Difference ^d (95% CI)	PCV13/PCV13%	PCV13%	Difference ^d (95% CI)
Local reactions													
Redness^a													
	Any	30.5	13.6	16.9(3.0;29.8)	28.0	20.0	8.0(-14.2;20.6)	26.5	26.5	-5.9(-19.8;8.2)	18.4	18.4	8.2(-5.8;21.5)
	Mild	24.1	9.3	14.8(1.3;27.3)	17.4	13.0	4.3(-18.1;20.6)	23.5	23.5	-2.9(-16.1;10.3)	17.0	17.0	6.4(-7.6;19.9)
	Moderate	16.3	4.1	12.2(0.7;22.8)	14.3	9.5	4.8(-16.4;25.6)	9.1	9.1	-3.0(-16.5;10.2)	2.6	2.6	0.0(-8.5;8.5)
	Severe	4.4	0.0	4.4(-2.9;11.4)	4.8	4.8	0.0(-14.8;14.8)	0.0	0.0	0.0(-5.9;5.9)	0.0	2.6	-2.6(-9.4;4.4)
Swelling													
	Any	31.0	12.1	19.0(6.1;30.5)	26.9	15.4	11.5(-8.7;30.2)	32.4	32.4	-8.1(-26.3;10.2)	26.5	26.5	-2.0(-15.3;11.3)
	Mild	18.9	11.3	7.5(-4.4;18.9)	4.0	8.0	16.0(-3.6;33.2)	17.1	25.7	-8.6(-24.7;8.2)	26.5	26.5	-4.1(-17.7;9.9)
	Moderate	16.3	2.0	14.3(3.5;23.9)	9.5	9.5	0.0(-19.1;19.1)	18.8	14.7	-2.9(-20.0;14.0)	5.4	5.4	-5.4(-13.7;3.4)
	Severe	2.3	0.0	2.3(-3.8;8.2)	4.8	0.0	4.8(-7.6;16.3)	0.0	0.0	0.0(-5.9;5.9)	0.0	0.0	0.0(-5.0;5.0)
Pain^b													
	Any	88.3	78.1	10.2(3.1;16.9)	86.3	84.9	1.4(-9.1;11.7)	7.8	81.9	-4.2(-14.6;6.9)	93.2	93.2	2.0(-2.5;6.6)
	Mild	83.8	73.5	10.3(2.1;18.1)	86.4	81.8	4.5(-7.1;15.9)	6.5	80.9	-4.4(-15.4;6.9)	90.6	90.6	2.2(-3.8;8.1)
	Moderate	52.4	28.6	23.8(9.4;36.7)	45.2	29.0	16.1(-2.9;33.2)	8.8	33.3	-9.5(-23.6;5.8)	65.5	35.5	21.0(6.2;34.5)
	Severe	12.2	8.2	4.1(-6.2;14.0)	7.4	4.3	13.0(-3.0;27.0)	0.0	0.0	0.0(-5.9;5.9)	0.0	5.4	-5.4(-13.7;3.4)
Limitation of arm movement^c													
	Any	47.2	30.6	16.7(3.5;28.9)	37.9	24.1	13.8(-9.4;35.2)	6.2	35.7	-9.5(-24.9;6.3)	32.9	50.0	2.9(-7.7;13.3)
	Mild	45.7	30.0	15.7(2.4;28.1)	34.5	24.1	10.3(-12.0;32.2)	0.0	34.1	-12.2(-28.3;5.4)	47.0	47.0	0.0(-11.9;11.9)
	Moderate	2.3	0.0	2.3(-3.8;8.2)	13.6	0.0	13.6(-3.0;28.0)	3.1	3.1	0.0(-5.8;5.8)	5.3	2.6	2.6(-4.4;9.4)
	Severe	8.3	4.2	4.2(-4.7;12.1)	10.0	0.0	10.0(-5.9;54.0)	0.0	0.0	0.0(-5.9;5.9)	2.6	2.6	0.0(-8.3;8.3)
Any local reaction^d		88.7	79.7	9.0(2.4;15.4)	89.3	86.7	2.7(-7.2;12.8)	4.4	81.1	1.4(-8.3;11.0)	85.4	94.7	0.7(-3.8;5.1)
Systemic Events													
Fever													
	Any (≥38 °C)	2.3	9.1	-6.8(-16.8;3.7)	4.8	0.0	4.8(-7.6;16.3)	0.0	0.0	0.0(-5.9;5.9)	2.6	0.0	2.6(-4.4;9.4)
	Mild (≥38 °C but <38.5 °C)	2.3	2.3	0.0(-7.5;7.5)	4.8	0.0	4.8(-7.6;16.3)	0.0	0.0	0.0(-5.9;5.9)	2.6	0.0	2.6(-4.4;9.4)
	Moderate (≥38.5 °C but <39 °C)	0.0	0.0	0.0(-4.4;4.4)	0.0	0.0	0.0(-8.9;8.9)	0.0	0.0	0.0(-5.9;5.9)	0.0	0.0	0.0(-5.0;5.0)
	Severe (≥39 °C but ≤40 °C)	0.0	0.0	0.0(-4.4;4.4)	0.0	0.0	0.0(-8.9;8.9)	0.0	0.0	0.0(-5.9;5.9)	0.0	0.0	0.0(-5.0;5.0)
	>40 °C	0.0	6.8	-6.8(-14.8;1.8)	0.0	0.0	0.0(-8.9;8.9)	0.0	0.0	0.0(-5.9;5.9)	0.0	0.0	0.0(-5.0;5.0)
	Fatigue	56.4	64.9	-8.5(-19.2;2.6)	8.6	68.6	0.0(-13.3;13.9)	1.1	62.3	-13.2(-27.5;2.6)	65.6	65.6	0.0(-10.7;10.7)
	Headache	57.3	61.0	-3.7(-15.4;8.5)	4.2	54.8	-2.4(-18.9;14.7)	2.2	51.2	-14.0(-27.2;0.6)	4.4	72.7	-11.4(-21.3;-0.9)
	Chills	32.8	25.9	6.9(-7.5;20.8)	6.7	33.3	-6.7(-24.5;12.2)	2.2	22.2	0.0(-13.6;13.6)	26.6	24.5	-1.9(-15.1;11.5)
	Rash	32.7	9.1	23.6(9.5;36.1)	17.2	27.6	-10.3(-29.4;10.2)	2.2	12.1	12.1(-2.9;25.8)	7.3	9.8	-2.4(-15.2;10.5)
	Vomiting	2.3	0.0	2.3(-3.8;8.2)	4.8	0.0	4.8(-7.6;16.3)	6.5	3.2	3.2(-5.3;11.4)	7.1	7.1	0.0(-10.0;10.0)
	Decreased appetite	21.6	19.6	2.0(-9.8;13.8)	4.5	31.0	3.4(-12.2;18.4)	7.7	20.6	-5.9(-21.8;10.6)	4.4	28.3	-1.9(-15.1;11.5)
	New generalized muscle pain	70.5	57.9	12.6(2.2;22.6)	17.7	56.5	15.2(-0.1;29.5)	0.0	47.7	2.3(-15.9;20.6)	27.8	69.0	-1.1(-12.8;10.5)
	Aggravated generalized muscle pain	40.0	25.0	15.0(0.1;28.9)	38.7	32.3	6.5(-9.5;21.8)	22.9	22.9	0.0(-19.1;19.6)	1.1	42.6	-6.6(-20.5;7.8)
	New generalized joint pain	23.2	25.0	-1.8(-12.4;9.0)	0.7	31.0	-10.3(-21.9;2.3)	3.3	21.6	2.7(-13.3;18.4)	15.5	35.2	-3.7(-18.0;10.8)
	Aggravated generalized joint pain	17.0	11.3	5.7(-5.7;16.8)	5.0	20.8	4.2(-11.2;18.6)	7.7	19.4	-2.8(-18.9;13.3)	0.0	25.0	0.0(-14.1;14.1)
	Any systemic event ^f	86.4	84.8	1.5(-4.9;7.9)	82.8	87.5	-4.7(-15.6;6.7)	7.6	79.1	-1.5(-13.5;10.8)	13.3	92.0	-3.6(-8.8;1.6)

^a Redness and swelling were categorized as absent if <2.5 cm, mild if ≥2.5 cm and ≤5.0 cm, moderate if >5.0 cm and ≤10.0 cm, and severe if >10.0 cm.

^b If pain at the injection site was present, subjects were asked to enter the severity as mild if the symptom was easily tolerated, moderate if there was discomfort sufficient to interfere with usual activity, and severe if the pain was incapacitating.

^c If limitation of arm movement was present, subjects were asked to enter the severity as mild if there was some limitation of arm movement, moderate if the subject was unable to move his or her arm above the head but able to move it above the shoulder, and severe if the subject was unable to move the arm above the shoulder.

^d Difference in proportions expressed as a percentage.

^e Any local reaction = any pain, any swelling, any redness, or any limitation of arm movement.

^f Any systemic event = any fever ≥38 °C, any fatigue, any headache, any chills, any rash, any vomiting, any decreased appetite, any new or aggravated generalized muscle pain, and any new or aggravated joint pain.

An acceptable safety profile was seen when PCV13 was followed 3.5–4 years later by PCV13 or PPSV23, irrespective of subject age. Subsequent vaccination with PPSV23 gave rise to more local reactions in those previously administered PCV13 or PPSV23 than did revaccination with PCV13.

A potential limitation is that the study was a non-prospective open label extension of a reported parent study [5]. However, all serological evaluations remained blinded throughout all stages of the study, and vaccine allocation in subjects aged 60–64 years was maintained through an electronic randomization system. Subjects that returned for the extension study did not differ in terms of baseline demographics, medical history or response to initial vaccination, when compared to subjects that did not return. The study also did not include a study arm evaluating the sequence of PPSV23 followed by PCV13 at a 3.5–4 year interval to evaluate the potential longer term impact of PPSV23 on subsequent PCV13 immune response. However, PPSV23 has been shown to dramatically decrease response to subsequent PCV7 or PCV13 administered 1 year later and results from this study demonstrate that the negative impact of PPSV23 on subsequent PPSV23 persists for at least 3.5–4 years, consistent with the inability of this T cell independent vaccine to prompt a recall response to antigens in common [19,20,23,27].

5. Conclusion

The present study documents the potential advantage of initial PCV administration, which permits the establishment of an immune state that results in appropriate recall responses upon subsequent immunization with either PCV13 or PPSV23. The study further demonstrates that PCV13 in a younger adult population results in higher responses compared to older adults. These responses can be sustained with a subsequent PCV13 dose when delivered at an appropriate interval, and can likely be expanded to include responses to the non-PCV13 serotypes with administration of PPSV23 later in life. Such an approach has the potential to provide protective immunity against significant disease-associated pneumococcal serotypes throughout an extended at-risk period of later adult life.

Acknowledgments

We would like to thank the investigators of the 6115A1-004 study group: Dr. Stanley Lawrence Block Jr., Dr. Kristina K. Bryant, Dr. Shane Glade Christensen, Dr. Donna M. DeSantis, Dr. Robert Wilson-Frenck Jr., Dr. David L. Fried, Dr. John E. Ervin, Dr. Max Helman, Dr. Dan C. Henry, Dr. Lisa Anne Jackson, Dr. Judith Lee Kirstein, Dr. Randle Thomas Middleton, Dr. Frederick Allen Martin, Dr. Terry L. Poling, Dr. Ernie Riffer, Dr. John Rubino, Dr. Renee Nilsson Scheidell, Dr. Donald R. Sislen, Dr. Mark Alan Turner, Dr. Martin van Cleeff, Dr. Keith Stewart Reisinger, Dr. John Jay Treanor

The authors wish to thank James Trammel and the programming staff at PharmaNet/i3 for support with data analysis; and at Pfizer Ltd Deepthi Jayawardene for statistical support, Carmel Devlin for regulatory support and Lynne Baxter for medical writing support.

Disclosure statement: AG, KUJ, DAS, EAE, WCG, and BS-T are current employees of Pfizer and may hold stock options. LAJ, MvC, RWF, and JT received funding from Pfizer to conduct this, and the previous study. LAJ received support from Pfizer for attendance at a scientific meeting. The Group Health Research Institute has received grants from Pfizer, Novartis, Inviragen, Sanofi-Pasteur, the National Institutes for Health and the Centers for Disease Control and Prevention. The Cincinnati Children's Hospital Medical Center has received research grants from Merck, Ligocyte, MedImmune and GlaxoSmithKline. JT received payments from Novartis and Immune

Targeting Systems for Scientific Advisory Board activities, and from Up to Date as royalties, and the University of Rochester Medical Center has received research grants from Protein Sciences Corporation, Ligocyte, Sanofi and GlaxoSmithKline. **Funding:** This study was funded and sponsored by Wyeth Vaccines Research, which was acquired by Pfizer Inc in October 2009. The sponsor and all authors were involved in the study design and the data collection, analysis, and interpretation of data, writing of the manuscript and in the decision to submit the manuscript for publication.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.vaccine.2013.04.084>.

References

- [1] Lynch 3rd JP, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. *Semin Respir Crit Care Med* 2009;30(2):189–209.
- [2] Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 1997;46(RR-8):1–24.
- [3] Centers for Disease Control and Prevention. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). *MMWR Morb Mortal Wkly Rep* 2010;59:1102–6.
- [4] Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. *J Infect Dis* 1998;178(3):870–4.
- [5] Jackson LA, Gurtman AG, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults. *Vaccine* 2013;31(35):3577–84.
- [6] World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. <http://www.wma.net/en/30publications/10policies/b3/index.html>; Amended October 2000 [accessed 09.11.12].
- [7] ICH topic E6 guideline for good clinical practice. Step 5, consolidated guideline. <http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html>; [accessed 09.11.12].
- [8] Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to *Streptococcus pneumoniae* serotypes 6C and 7A. *Vaccine* 2011;29:7207–11.
- [9] Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, Santosham M, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. *Vaccine* 2007;25:3816–26.
- [10] Chan ISF, Zhang Z. Test based exact confidence intervals for the difference of two binomial proportions. *Biometrics* 1999;55:1201–9.
- [11] Centers for Disease Control and Prevention. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. *MMWR*, June 1 2012;61(21):394–5.
- [12] Torling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. *Vaccine* 2003;22:96–103.
- [13] Richmond P, Kaczmarek E, Borrow R, Findlow J, Clark S, McCann R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. *J Infect Dis* 2000;181:761–4.
- [14] Borrow R, Goldblatt D, Andrews N, Richmond P, Southern J, Miller E. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. *J Infect Dis* 2001;184:377–80.
- [15] Brynjolfsson SF, Henneken M, Bjarnarson SP, Mori E, Del Giudice G, Jonsdottir I. Hyporesponsiveness following booster immunization with bacterial polysaccharides is caused by apoptosis of memory B cells. *J Infect Dis* 2012;205:422–30.
- [16] Clutterbuck EA, Lazarus R, Yu LM, Bowman J, Bateman EA, Diggle L, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. *J Infect Dis* 2011;205(9):1408–16.
- [17] Goldblatt D, Borrow R, Miller E. Natural and vaccine-induced immunity and immunologic memory to *Neisseria meningitidis* serogroup C in young adults. *Clin Infect Dis* 2002;185:397–400.
- [18] de Roux A, Schmöle-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. *Clin Infect Dis* 2008;46(7):1015–23.

- [20] Gruber WC, Scott DA, Emini EA. Development and clinical evaluation of Prevnar 13, a 13-valent pneumococcal CRM(197) conjugate vaccine. *Ann N Y Acad Sci* 2012;1263(1):15–26.
- [21] Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions. *MMWR*, October 12, 2012;61(40):816–9.
- [22] Greenberg RN, Gurtman A, Frenck R, Strout C, Jansen KU, Jayawardene D, et al. A phase 3, randomized, active-controlled trial to evaluate the safety, tolerability, and immunogenicity of sequential administration of 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) administered at 1-year intervals in PPSV23-naïve adults 60–64 years of age (Abstract 665). In: Presented at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA). 2011.
- [23] Shelly MA, Jacoby H, Riley GJ, Graves BT, Pichichero M, Treanor JJ. Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. *Infect Immun* 1997;65(1):242–7.
- [24] Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50–80 years. *Clin Infect Dis* 2009;49(9):1318–25.
- [25] Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska native adults 55–70 years of age. *Clin Infect Dis* 2009;49:241–8.
- [26] Horne AD, Lachenbruch PA, Getson PR, Hsu HS. Analysis of studies to evaluate immune response to combination vaccines. *Clin Infect Dis* 2001;33(Suppl. 4):S306–11.
- [27] Jackson L, Gurtman A, Rice K, Pauksens K, Greenberg R, Jones T, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. In: Presented at the 21st Annual Meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). 2011.